CVE-2015-3965
UnknownEPSS 2.94%
Last modified
CVE-2015-3965 is a vulnerability of currently unknown severity. Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.. EPSS estimates a 2.94% chance of exploitation in the next 30 days.
Description
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
Metrics
Weakness Enumeration
Affected Software
| Vendor | Product | Versions |
|---|---|---|
| Pfizer | Symbiq Infusion System Firmware | <= 3.13 |
References
- https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01Third Party Advisory, US Government Resource
- https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01Third Party Advisory, US Government Resource
Timeline
- Published
- Last Modified
- Status
- Modified
Frequently Asked Questions
What is CVE-2015-3965?
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
How severe is CVE-2015-3965?
Severity scoring for CVE-2015-3965 is pending analysis. The EPSS model estimates a 2.94% probability of exploitation in the next 30 days.
How do I fix CVE-2015-3965?
Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.
Are you affected by CVE-2015-3965?
Run a free Strix scan to check your systems for this vulnerability.
Scan your code nowSource: NVD / NIST